1. Introduction
===============

Pancreatic cancer is one of the most lethal malignant tumors worldwide, with an estimated five-year survival rate of only about 5%.^\[[@R1]\]^ This means that early and accurate diagnosis of pancreatic cancer may help improve the survival of patients and is urgently required. To date, the diagnosis of pancreatic cancer relies on imaging methods, which are insufficient in some situations.^\[[@R2]\]^ Therefore, identifying a diagnostic and prognostic biomarker has great clinical significance for patients with pancreatic cancer.

Cancer is regarded as a disease involving genome changes.^\[[@R3]\]^ DNA replication, which affects genomic stability, plays an important role in the initiation and progression of tumors. *TYMS*, located on chromosome 18p, encodes thymidylate synthase (TS), an enzyme involved in the replication and repair of DNA.^\[[@R4]\]^ TS plays an important role in DNA replication by catalyzing the methylation of dUMP to produce dTMP.^\[[@R5]\]^ Some studies have described *TYMS* expression, suggesting that it plays a role in cancer.^\[[@R4],[@R6]\]^ However, the role of *TYMS* expression in the diagnostic and prognostic evaluation of patients with pancreatic cancer remains unclear.

In this study, we compared *TYMS* expression in patients with pancreatic cancer and healthy people, and evaluated the diagnostic value of *TYMS* in pancreatic cancer using ROC. We also investigated the correlation between clinical characteristics and *TYMS* expression, and discussed the prognostic role of *TYMS* in overall survival (OS) and recurrence-free survival (RFS) in patients. Finally, we explored whether *TYMS* could be a biomarker for the diagnostic and prognostic evaluation of patients with pancreatic cancer.

2. Methods
==========

2.1. Data mining and collection
-------------------------------

Data generated from patients with pancreatic cancer and RNA-seq results were downloaded using the RTCGAToolbox package in R (version 3.5.1) from The Cancer Genome Atlas (TCGA) database.^\[[@R7],[@R8]\]^ As a public database, ethics approval and patient consent were not applicable. The number of patients included in our analysis was 173, and the number of normal individuals was 4.

2.2. Statistical analysis
-------------------------

Box-plots were used to compare *TYMS* expression between different groups. ROC was applied to test the diagnostic value of *TYMS*, and patients were divided into 2 groups (high *TYMS* expression and low *TYMS* expression) based on thresholds set using pROC packages.^\[[@R9]\]^ Chi-square and Fisher exact tests were used to examine the correlation between *TYMS* expression and clinical characteristics in patients. Kaplan--Meier curves were used to investigate OS and RFS, grouped by *TYMS* expression, using the Survival package in R.^\[[@R10],[@R11]\]^ Univariate Cox analysis was used to select the variables related to OS and RFS. Finally, Multivariate Cox analysis was used to check the effects of *TYMS* expression on the survival of patients, and other pathological features. *P* \< .05 was considered statistically significant.

3. Results
==========

3.1. Patients' characteristics
------------------------------

A total of 173 patients and 4 normal individuals were included in this analysis, and their clinical data were mined and downloaded from the TCGA database. Included in this study were 77 (44.51%) females and 96 (55.49%) males. There were 140 (80.92%) patients older than 55 years, and 33 (19.08%) patients younger than 55 years. Detailed patient characteristics are presented in Table [1](#T1){ref-type="table"} .
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Clinical characteristics of the patients with pancreatic cancer.
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Clinical characteristics of the patients with pancreatic cancer.
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3.2. TYMS is upregulated in pancreatic cancer
---------------------------------------------

*TYMS* expression was compared between pancreatic cancer samples and normal tissues (Fig. [1](#F1){ref-type="fig"}). Our results show that *TYMS* is highly expressed in pancreatic cancer. Moreover, *TYMS* expression significantly differed in vital status (*P* = .0038) subgroups.

![*TYMS* was upregulated in pancreatic cancer. Expression of *TYMS* in normal tissues and pancreatic cancer samples with different stages, T classification, N classification, M classification, histologic grade, residual tumor, and vital status.](medi-98-e18487-g003){#F1}

3.3. Diagnostic value of TYMS
-----------------------------

We performed ROC analysis of data from patients and healthy people to measure the diagnostic value of *TYMS*. The AUC was 0.675, representing a moderate diagnostic value for pancreatic cancer (Fig. [2](#F2){ref-type="fig"}). Subgroup analysis further demonstrated the diagnostic value of PES1 expression in distinct stage, with AUC of 0.562 for stage I, 0.691 for stage II, 0.667 for stage III and 0.450 for stage IV.

![*TYMS* represented a moderate diagnostic value. The ROC of normal tissues and all pancreatic cancer samples, and subgroup analysis for stage I, II, III, and IV pancreatic cancer.](medi-98-e18487-g004){#F2}

3.4. Correlation between clinical characteristics and TYMS expression in pancreatic cancer
------------------------------------------------------------------------------------------

We divided patients into *TYMS* high and low expression groups and examined the correlation between clinical characteristics and *TYMS* expression in patients with pancreatic cancer (Table [2](#T2){ref-type="table"}). The correlation between *TYMS* expression and clinical characteristics, including therapy outcome (*P* = .0401), vital status (*P* = .027), and OS (*P* = .0325) was significant.

###### 

Association between the clinical features and TYMS expression in patients with pancreatic cancer.
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3.5. High TYMS expression is associated with poor OS in patients with pancreatic cancer
---------------------------------------------------------------------------------------

Kaplan--Meier curves of OS showed that higher *TYMS* expression was associated with worse OS (*P* = .014) (Fig. [3](#F3){ref-type="fig"}). Subgroup analysis further indicated that high *TYMS* expression significantly affected the OS of patients in histologic grades G1/G2 (*P* = .025) and clinical stages I/II (*P* = .023). Univariate analysis revealed that histological type (*P* = .001), T classification (*P* = .009), N classification (*P* = .002), residual tumor (*P* = .018), and TYMS expression (*P* = .014) were associated with poor OS. Multivariate analysis including age, gender, histological type, stage, T/N/M classification, residual tumor, and *TYMS* expression parameters further showed that *TYMS* is an independent risk factor for OS in patients with pancreatic cancer (HR = 1.62, 95% CI: 1.05--2.48, *P* = .028; Table [3](#T3){ref-type="table"}).

![Kaplan--Meier curves of overall survival in patients with pancreatic cancer: in all tumors; histologic grades G1/G2 and G3/G4; and clinical stages I/II and III/IV.](medi-98-e18487-g006){#F3}
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Univariate and multivariate analysis of overall survival in patients with pancreatic cancer.
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3.6. High TYMS expression is associated with poor RFS in patients with pancreatic cancer
----------------------------------------------------------------------------------------

We generated Kaplan--Meier curves of RFS (Fig. [4](#F4){ref-type="fig"}). Upregulation of *TYMS* was associated with poor RFS in patients with pancreatic cancer (*P* = .021). Subgroup analysis revealed that *TYMS* upregulation was associated with poor RFS in clinical stage I/II (*P* = .0038). Univariate analysis revealed that N classification (*P* = .017), residue tumor (*P* = .002), and *TYMS* expression (*P* = .013) were associated with poor RFS (Table [4](#T4){ref-type="table"}). Multivariate analysis further confirmed *TYMS* as an independent risk factor for RFS in patients with pancreatic cancer (HR = 1.92, 95% CI: 1.13--3.28, *P* = .016).

![Kaplan--Meier curves of recurrence-free survival in patients with pancreatic cancer: in all tumors; histologic grades G1/G2 and G3/G4; and clinical stages I/II and III/IV.](medi-98-e18487-g008){#F4}
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Univariate and multivariate analysis of recurrence-free survival in patients with pancreatic cancer.
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4. Discussion
=============

Our team has been working toward developing novel biomarkers for distinct tumors.^\[[@R12],[@R13]\]^ In this study, we report that *TYMS* is upregulated in pancreatic cancer and that elevated *TYMS* expression is associated with therapy outcome, vital status, and OS of patients. Kaplan--Meier curves of OS and RFS also showed that high *TYMS* expression is correlated with poor survival in patients. Moreover, univariate and multivariate analyses suggest that *TYMS* expression plays a prognostic role in patients with pancreatic cancer. Our results indicate that *TYMS* is insufficient for use as a diagnostic biomarker, but the prognostic capacity of *TYMS* is sufficient.

High *TYMS* expression has been reported in breast cancer,^\[[@R14]\]^ non-small cell lung cancers,^\[[@R15]\]^ and prostate cancer.^\[[@R6],[@R16]\]^ However, *TYMS* expression levels in pancreatic cancer were unknown. Our results demonstrate that *TYMS* is upregulated in pancreatic cancer. This result is consistent with those previously reported in other tumors. Moreover, different *TYMS* expression levels were found in distinct histologic grades and vital status, suggesting that *TYMS* plays an important role in the progress and prognosis of pancreatic cancer. However, because the AUC of ROC was relatively low, the diagnostic value of *TYMS* was moderate.

*TYMS*, encodes an enzyme that participates in the synthesis of DNA and its role in the proliferation of tumor cells has been reported. Patients with advanced clinical stage prostate cancer more commonly express *TYMS* than do those with less advanced disease.^\[[@R16]\]^ In colorectal cancer, knockdown of *TYMS* inhibits the proliferation of tumor cells and promotes apoptosis.^\[[@R17]\]^ Our results, that patients with poorer vital status or OS had higher *TYMS* expression levels, are consistent with these observations.

*TYMS* expression is associated with decreased survival in lung carcinoma,^\[[@R15],[@R18]\]^ metastatic colorectal cancer,^\[[@R19]\]^ and hepatocellular carcinoma.^\[[@R20]\]^ Our results, consistent with those reported in other cancers, show that high *TYMS* expression correlates with poorer OS in patients with pancreatic cancer. We also found that high *TYMS* expression affects the OS of patients in histologic grades G1/G2 and clinical stages I/II, but not in histologic grades G3/G4 and clinical stages III/IV. These data suggest that *TYMS* has different roles in patients with distinct stages.

Surgery is the only way to cure pancreatic cancer.^\[[@R21]\]^ However, tumor recurrence adversely impacts the effectiveness of surgery, which complicates treatment choice. Here, we also show that high *TYMS* expression leads to poorer RFS in patients with pancreatic cancer, indicating that *TYMS* expression levels can be used to inform treatment choice. Moreover, we found high *TYMS* expression significantly affected the RFS of patients in clinical stages I/II, rather than in clinical stages III/IV, indicating a powerful prognostic capacity during an early stage. However, the prognostic role of *TYMS* in patients was limited in histologic grades G3/G4. Exploring more potential grade G1/G2 biomarkers in patients with pancreatic cancer in the near future is important. Limitations of our study included the small sample size in some comparison groups, and that tissue collection was very difficult in some cases given that operations were not suitable for patients with late stage pancreatic cancer. In addition, some types of pancreatic cancer were rarely observed.

Our results show that *TYMS* plays a significant role in the diagnosis and prognosis of patients with pancreatic cancer. These results contribute to the collective understanding of the role of *TYMS* in the diagnosis and prognosis of patients with cancer. The application of *TYMS* in prognosis is limited in histologic grades G3/G4, and a novel biomarker in histologic grades G1/G2 of patients with pancreatic cancer is urgently required in the future.

In conclusion, we show that, in patients with pancreatic cancer, higher *TYMS* expression is associated with advanced clinical stages and undesirable prognosis, and that *TYMS* could be used as a biomarker for diagnostic and prognostic evaluation in patients with pancreatic cancer.
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